Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis

doi:10.5498/wjp.v9.i3.47

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 3

This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8547)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

483

WORD

196

HTML

5818

Tables (1-2)

259

Sum=6756

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

929

Download

862

Sum=1791

Jun 10, 2019 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Psychiatr. Jun 10, 2019; 9(3): 47-54
Published online Jun 10, 2019. doi: 10.5498/wjp.v9.i3.47

Table 2 Summary of studies

Name of study	Yr	Country of origin	Total number of participants	Age	Type of setting	Comparators	Duration
Meltzer et al[23]	2010	United States	60	Mean age 70.9 yr	Unclear	Pimavanserin vs placebo	4 wk
Cummings et al[24]	2014	United States and Canada	199	Mean age 72.4 yr	Academic hospitals and neurology research centers	Pimavanserin vs placebo	6 wk

Citation: Tampi RR, Tampi DJ, Young JJ, Balachandran S, Hoq RA, Manikkara G. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatr 2019; 9(3): 47-54
URL: https://www.wjgnet.com/2220-3206/full/v9/i3/47.htm
DOI: https://dx.doi.org/10.5498/wjp.v9.i3.47